NCT03855722 Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)
| NCT ID | NCT03855722 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helsinki University Central Hospital |
| Condition | Transplant Dysfunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 496 participants |
| Start Date | 2019-03-12 |
| Primary Completion | 2022-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 496 participants in total. It began in 2019-03-12 with a primary completion date of 2022-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Remote ischemic preconditioning (RIPC) is a concept where remotely induced ischemia produces protection against ischemia-reperfusion injury in a remote organ. RIPC has been studied extensively in animal models and heart surgery, but it's benefit in transplantation has been studied less. The primary aim of this study is to find out whether RIPC performed in a donor in donation after brain-death (DBD) could improve delayed graft function rate of kidney transplants.
Eligibility Criteria
Donor Inclusion Criteria: * Brain-dead organ donor with a plan of harvesting at least one kidney Donor Exclusion Criteria: * Haemodynamically unstable donor * Age below 18 years * Planned organ recipients are recruited to another prospective trial, which prevents participation in this trial. All organ recipients receiving organs (kidney, liver, pancreas-kidney, heart, lungs) from a randomized donor will be recruited providing that the recipient surgery is performed at Helsinki University Hospital, recipient is over 18 years old, and recipient gives written informed consent to participate in the trial.
Contact & Investigator
Aki Uutela, MD
PRINCIPAL INVESTIGATOR
Helsinki University Central Hospital
Frequently Asked Questions
Who can join the NCT03855722 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Transplant Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03855722 currently recruiting?
Yes, NCT03855722 is actively recruiting participants. Contact the research team at ville.sallinen@helsinki.fi for enrollment information.
Where is the NCT03855722 trial being conducted?
This trial is being conducted at Helsinki, Finland.
Who is sponsoring the NCT03855722 clinical trial?
NCT03855722 is sponsored by Helsinki University Central Hospital. The principal investigator is Aki Uutela, MD at Helsinki University Central Hospital. The trial plans to enroll 496 participants.